Chemometec — August 2020
-
https://medcitynews.com/2020/07/bms-bluebird-refile-fda-approval-application-for-car-t-therapy-in-myeloma/
“FDA is likely to grant the priority review given the strength of data from the Phase II KarMMa study on which the application was based, which included a median progression-free survival of 12.1 months, compared with three months for the standard of care, along with its existing breakthrough therapy designation and an unmet need in late-line multiple myeloma” -
Verus - for nuværende er CAR-T langt fra 1. linie og formentlig også 2. linie. Det vil udelukkende blive brugt i meget syge patienter. Over tid bliver deet måske anderledes - specielt hvis der kommer off the shelf CAR-T, så det meget omstændige udebliver........og hermed også en mere tilforladelig pris.
-
God morgen.
-
god formiddag, fin udvikling den seneste tid må man sige, det er virkelig bare en aktie er svær at finde gode suppleringsmuligheder i, i form af store dyk
spændende om 400 holder idag! -
God morgen.
-
Enig Verus. Jeg ville nok ikke gå ind i den i det her niveau. Men mit gak er også lavere end 200, så derfor er det interresant for mig. Umiddelbart bør der ikke være noget der kan regulere kursen i det niveau vi så idag, med mindre det er en stor opjustering eller andet godt nyt.
-
Test
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind